Skip to main content

Advertisement

Bilobalide modulates serotonin-controlled behaviors in the nematode Caenorhabditis elegans

BMC Neurosciencevolume 10, Article number: 62 (2009) | Download Citation

Abstract

Background

Dysfunctions in the serotonergic system have been implicated in several neurological disorders such as depression. Elderly individuals who have been diagnosed with clinical depression show elevated cases of neurodegenerative diseases. This has led to suggestions that modulating the serotonin (5-HT) system could provide an alternative method to current therapies for alleviating these pathologies. The neuroprotective effects of bilobalide in vitro have been documented. We aim to determine whether bilobalide affects the 5-HT system in the nematode C. elegans. The wild type worms, as well as well-characterized 5-HT mutants, were fed with bilobalide in a range of concentrations, and several 5-HT controlled behaviors were tested.

Results

We observed that bilobalide significantly inhibited 5-HT-controlled egg-laying behavior in a dose-dependent manner, which was blocked in the 5-HT receptor mutants (ser-4, mod-1), but not in the 5-HT transporter (mod-5) or synthesis (tph-1) mutants. Bilobalide also potentiated a 5-HT-controlled, experience-dependent locomotory behavior, termed the enhanced slowing response in the wild type animals. However, this effect was fully blocked in 5-HT receptor mod-1 and dopamine defective cat-2 mutants, but only partially blocked in ser-4 mutants. We also demonstrated that acetylcholine transmission was inhibited in a transgenic C. elegans strain that constitutively expresses Aβ, and bilobalide did not significantly affect this inhibition.

Conclusion

These results suggest that bilobalide may modulate specific 5-HT receptor subtypes, which involves interplay with dopamine transmission. Additional studies for the function of bilobalide in neurotransmitter systems could aid in our understanding of its neuroprotective properties.

Background

Serotonin (5-HT) modulates several behaviors in both vertebrate and invertebrate systems and plays an important role in neuronal plasticity and survival. It has also been associated with behavioral deficiencies seen in Alzheimer's patients [1]. The serotonergic system is particularly interesting because of its interactions with many other neurotransmitters systems, such as glutamate, acetylcholine and GABA [2]. In AD, there are drastic decreases in excitatory neurotransmitters, whilst the inhibitory effects of 5-HT on these systems remains relatively stable [3]. These findings have led to suggestions that antagonizing 5-HT receptors, specifically the 5-HT1 receptor subtype, could provide an alternative or an adjunct, to current AD therapies. Previous research has found that induced cholinergic and glutamatergic dysfunction [4] were both alleviated by treatment with 5-HT1A antagonist WAY 100 635. Experimental evidence also supports a role for 5-HT receptors in learning and memory [2]. Administration of selective serotonin reuptake inhibitors (SSRIs) was reported to stimulate hippocampal neurogenesis in adult rats; and this increase is modulated through different 5-HT receptor subtypes [5]. These studies strongly support physiological, pathophysiological as well as therapeutic roles linking the serotonergic system with cognitive processes.

In the process of identifying behavioral phenotypes of a neuronal amyloid β (Aβ) expressing Caenorhabditis elegans strain, we discovered a change of sensitivity to serotonin (5-hydroxytryptamine 5-HT), which was restored by feeding the worms with the Ginkgo biloba extract EGb 761 and some of it's constituents [6]. This result led us to hypothesize that certain pharmacologically active constituents of the extract are responsible for protecting the worms against Aβ toxicity; partially through modulation of 5-HT transmission.

Bilobalide, a sesquiterpene trilactone that accounts for approximately 3% of EGb 761 has been shown in many cases to be neuroprotective; particularly in models of acute neurodegeneration and Parkinson's disease. It has been reported that bilobalide protects against glutamatergic excitotoxicity both in vitro and in vivo [7–9] by antagonizing GABA receptors [10]. Bilobalide has also been shown to inhibit N-methyl-D-aspartate-induced activation of phospholipase A2 and its resultant phospholipid breakdown [7]. In combination with its inhibition of glutamate-induced death on rat cerebellar granule neurons, this has led to suggestions that bilobalide may be useful in the treatment of certain neurological disorders. In addition to these results, a high dose of bilobalide (100 μM) was shown to reduce the release of excitatory neurotransmitters [11]. In the present study, we seek to test the hypothesis that modulation of the 5-HT system by bilobalide may attribute to its neuroprotective properties.

In C. elegans, several behaviors are controlled by the 5-HT system [12, 13]. Similar to mammals, there are two major classes of 5-HT receptors in C. elegans. Table 1 provides a summation of the different C. elegans mutants and their specific mechanisms and/or functions that were utilized in this study. Comparisons are made between the C. elegans mutants and their mammalian homologues. As illustrated in table 1, the mod-1 receptor encodes an ionotropic 5HT receptor [14]. Ser-1, ser-4, and ser-7 are members of the metabotropic G-protein-coupled 5HT receptor superfamily [15–17]. Using the available 5-HT transmission mutants (Table 1) and 5-HT controlled behavioral assays, possible genetic targets of bilobalide were demonstrated in the present study.

Table 1 C. elegans 5-HT mutants with respect to mammalian counterparts
Full size table

Results

1. Inhibition of 5-HT stimulated egg-laying behavior by bilobalide requires serotonin receptors mod-1 and ser-4

Egg-laying is one of several well-defined behaviors C. elegans that are controlled by 5-HT. Exogenous levels of 5-HT can stimulate egg-laying behavior, a response extremely useful in identifying the action of drugs on specific neurotransmitter pathways [18, 19]. To determine if bilobalide alters 5-HT stimulated egg-laying, the wild type worms (adult day 1, 30 each group) were fed with bilobalide (BB) from L1 young larvae, followed by the egg-laying assay. When several concentrations of BB ranging from 0.003 to 30 μM was administered to the worms, a dose-dependent inhibition by BB was statistically significant at concentrations of 0.03 and 0.3 μM (n = 3, p < 0.05 Fig 1A) suggesting a specificity of this inhibition. However, concentrations higher than 3 μM were not statistically different from the control (data not shown).

Figure 1
figure1

Serotonin stimulated egg-laying and survival assay. (A) Wild type young larvae (L1) were fed with bilobalide (BB) ranging from 3 nM to 3 μM for 4 days. The number of eggs was scored 60 minutes after 5-HT (5 mg/ml) was added in 96-well plates (*p < 0.05, **p < 0.001). (B) Egg-laying response to BB in wild type and 5-HT mutants adult day 1 worms. (C) Wild type adult day 1 worms (8 from each group) were fed with Bilobalide (BB) (0.3 μM) from L1 stage. Animals were then pre-incubated with dopamine for 2 h before being placed in a 5-HT solution. The bars represent the mean of the number of eggs from three individual assays; *p < 0.05. (D) Life span assay in N2 C. elegans fed either Bilobalide (BB) 0.3 μM (closed circle, bilobalide), WAY 100 635 (open squares, WAY 100 635) 0.3 μM or the vehicle control (open circle, Ctrl). Worms were transferred for 4 consecutive days during their egg-laying phase, and then every other day after the egg-laying phase was completed. Data are expressed as the percentage (%) of survival in an age-synchronized population. Three independent experiments were performed with number of worms totaling 200.

Full size image

We then sought to identify where BB might disrupt serotonergic neurotransmission. The tph-1 mutant has a deletion in the 5-HT biosynthetic enzyme, tryptophan hydroxylase. This mutant lacks any detectable 5-HT and accumulates an excess amount of fertilized eggs [20], although its egg-laying circuitry remains responsive to exogenous 5-HT. The mod-5 mutant (Fig. 2) encodes for the only serotonin reuptake transporter (SERT) that has been discovered in C. elegans [21]. mod-1 encodes an ionotropic 5-HT receptor (5-HTR) [14] and SER-4 is a member of metabotropic G-protein coupled receptors, similar to mammalian 5-HT2 and 5-HT1A subtypes [16]. Both of these receptor subtypes are expressed in the neurons. When 5-HT stimulated egg-laying was scored in wild type and four 5-HT system defective mutants (tph-1, mod-5, mod-1 and ser-4) treated with BB, the inhibitory effect by BB was blocked in mod-1 and ser-4 mutants. The tph-1 and mod-5 mutants respond to BB in a similar manner as wild type (Fig. 1B), which suggest that the presynaptic component may not be required for the effect of BB on this particular behavior. These results indicate that the 5-HT receptors (mod-1 and ser-4) (Fig. 2) may be necessary for the BB effect in the egg-laying assay.

Figure 2
figure2

Schematic diagram of the neurotransmitter controlled behaviors and the associated mutant used in this study. The CAT-2 gene encodes for tyrosine hydroxylase and is the primary pathway for dopamine (DA) synthesis. Serotonin synthesis requires the TPH-1 tryptophan hydroxylase gene. Serotonin is removed from the synaptic space by the MOD-5 serotonin reuptake transporter. MOD-1 receptor encodes an ionotropic 5HT receptor and SER-4 belongs to the class of metabotropic G-protein-coupled 5HT receptors, and is homologous to mammalian 5-HT1 receptor class. The drug aldicarb is a cholinesterase inhibitor that causes an accumulation of acetylcholine at the neuromuscular junction, which eventually leads to paralysis. Exogenous 5-HT can inhibit this behavior. 5-HT stimulates egg-laying in C. elegans and both dopamine and acetylcholine inhibit it.

Full size image

Since BB displayed inhibitory effects on 5-HT stimulated egg-laying, we next sought to determine if it would interact with a known inhibitor of egg-laying in C. elegans, the neurotransmitter dopamine (DA) [19]. Various concentrations of BB failed to inhibit egg-laying in the cat-2 DA mutant (data not shown). In wild type animals that were pre-incubated with increasing concentrations of exogenous DA, there was a dose-dependent inhibition of their egg-laying behavior (Fig. 1C). Wild type worms that were fed BB (0.3 μM) and then pre-treated with DA for 2 h before 5-HT stimulated egg-laying assay did not show an inhibition in egg-laying by DA (Fig. 1C). In fact, the egg-laying response was similar to the response seen in the wild type worms with no treatment at all (Ctrl. 100% ± 1.1, BB 62.7% ± 1.3 p < 0.05) (DA 3 mg/ml 92% ± 3.5, BB 50.3% ± 4.2) (DA 6 mg/ml 65.4% ± 4.1, BB 103% ± 3.2 p < 0.05).

Since bilobalide had a significant effect on 5-HT-controlled egg-laying, we wanted to determine whether it, or a known 5-HT receptor antagonist WAY 100 635 (0.3 μM), would have any impact on life span and to ensure that the results seen with BB treatment were not a consequence of toxicity. Neither BB (0.3 μM) nor WAY 100 635 significantly affected the life span of wild type worms (Fig 1D, BB: 13.76 ± 0.54; WAY 100 635:13.97 ± 0.6; control group: 13.8 ± 0.31). This result excludes the possibility of a general effect by bilobalide on the life span of C. elegans.

2. Bilobalide potentiates a 5HT controlled experience-dependent locomotory behavior

We decided to utilize the basal and enhanced slowing responses (BSR and ESR, illustrated in Fig. 3A), which are measures of behavioral plasticity in the worms, to determine the effect of BB on an experience-dependant behavior. The slowing responses are used to associate prior feeding experience with response to food. This makes these responses a type of associative learning behavior (Fig. 3A). In the worms, the basal and enhanced slowing responses are mediated by dopamine and serotonin, respectively. Sawin et al. demonstrated that mod-1 mutant worms were defective in the 5-HT controlled enhanced slowing response. This group also reported that cat-2 (e1112) mutants that are deficient in the enzyme tyrosine hydroxylase, which is required for the synthesis of dopamine (DA), have normal serotonergic transmission but are defective in the DA mediated basal slowing response [12]. This same study also showed that when these animals are pre-incubated with exogenous DA, the basal slowing response is rescued. In the present study, we show that feeding the worms 0.3 μM of BB for three days before the assay significantly potentiated the ESR in wild type worms (Fig. 3B). However, this enhancement by BB was completely blocked in the mod-1 (Fig. 3C) and cat-2 (e1112) (Fig. 4C), p = 0.04, but not in ser-4 (Fig. 3E), mutant animals. Previous studies have reported that deficiencies in the serotonin receptors could lead to defects in the enhanced slowing response [14]; although a mod-5 mutation leads to a hyper-enhanced slowing response [21]. In the presents study, the ser-4 mutant animals did not show any abnormalities in the ESR, although there were slight changes in the BSR for both ser-4 and mod-1 (Fig. 4C&E). These results suggest that another mechanism for the neuroprotective effects of BB may involve altering the serotonergic as well as the dopaminergic system.

Figure 3
figure3

Serotonin-controlled learning behavioral. A. Schematic diagram of Slowing Responses in C. elegans. The basal and enhanced slowing responses (BSR), which are mediated by dopamine and serotonin, respectively are used to associate previous feeding experience. For the basal slowing response worms are well fed up until they are assayed. For the enhanced slowing response (ESR), there is a 30 min starvation period before they are assayed. (B) Basal (BSR) and enhanced (ESR) slowing responses in wild type animals fed with control or bilobalide (BB). (C) BSR and ESR in the mod-1 mutant worms fed with vehicle control or treated with BB. (D) BSR and ESR in the cat-2 mutant worms control or treated with BB. Four separate trials were performed for each strain. Error Bars represent the standard error; asterisk; p < 0.05, Student's t test. (E) BSR and ESR in the ser-4 mutant worms fed with vehicle control or with BB.

Full size image
Figure 4
figure4

Aldicarb Sensitivity Assay. (A) Wild type (wt) or worms that constitutively express human amyloid beta in the muscle cells (CL2006) were pre-incubated for 2 hours on plates with or without 2 mM of 5-HT. Aβ worms (CL2006), exhibit a natural resistance to aldicarb, in comparison to wild type controls. Each group contained 30 animals that were placed on 1 mM of aldicarb and scored until death. (B) Aβ worms (CL2006) were fed BB (0.3 μM) then pre-treated with 2 mM of exogenous 5-HT for 2 hrs. BB treatment has no effect on aldicarb sensitivity in transgenic Aβ worms (CL2006) pre-exposed to 5-HT. Data was obtained from three independent experiments. Each group consisted of 30 worms.

Full size image

3. Animals that constitutively express Aβ show reduced aldicarb sensitivity

In the presence of the acetylcholinesterase inhibitor aldicarb, accumulation of acetylcholine (ACh) in the synapse causes the worms to paralyze; which is inhibited by 5-HT [22]. This assay was adapted to determine the impact of Aβ-expression on the interaction between 5-HT and ACh. Wild type worms (Fig 4A. open circles) were exposed to 1 mM aldicarb and scored for progressive paralyses every 20 min. In Fig. 4A (filled circles), animals that were pre-incubated with 5-HT show a decrease in aldicarb sensitivity. Next, we compared the aldicarb sensitivity phenotype in wild type (N2) and a C. elegans mutant that constitutively expresses human amyloid beta in the muscle cells (CL2006). The results show that Aβ mutants (Fig. 4A, open squares, CL2006) were more resistant to aldicarb exposure than the wild type worms (open circles, N2, Fig. 4A) indicating a defect in ACh transmission in the Aβ strain. When Aβ mutants were pre-incubated with 5-HT (filled squares, CL2006 w/5-HT, Fig. 4A), their paralyses were remarkably delayed compared with wild type worms pre-incubated with 5-HT (filled circles N2 w/5-HT Fig. 4A) or the Aβ mutants that were not pre-incubated with 5-HT (open squares, CL2006). These results extend our previous findings [6] and suggest that Aβ expression alters both 5-HT as well as ACh transmission in C. elegans.

We next wanted to elucidate whether BB modulates Aβ-reduced aldicarb sensitivity. The mutant worms were fed BB (0.3 μM) for 4 days and then pre-incubated for 2 hrs on 1 mM of 5-HT followed by the aldicarb paralysis assay. Interestingly, the Aβ worms fed with BB (0.3 μM open squares, control Fig. 4B) did not rescue the impairment compared with non-treated controls (filled squares, control (Fig. 4B), indicating that BB is not specific to Ach transmission as well as its associated effect by Aβ expression.

Discussion

Serotonin has been shown to modulate many different behaviors in the nematode C. elegans. In the present study, we demonstrate a novel mechanism by which bilobalide (BB) modulates behavioral plasticity in C. elegans by antagonistically regulating serotonergic receptors. BB antagonizes egg-laying behavior via modulation of ionotropic MOD-1 and metabotropic SER-4 receptors in C. elegans, which are homologues to mammalian GABA-gated chloride channels and 5-HT1A/5-HT2A receptors, respectively. In addition, we demonstrated that Aβ expression in the worms reduced their sensitivity to aldicarb, an acetylcholinesterase inhibitor (AChEI). However, BB did not affect this behavior. Our results suggest that modulation of the 5-HT system by BB partially underlies its neuroprotective and efficacious effects in several in vitro systems [8–11]. Recent studies revealed a role of 5-HT receptors (5-HTR) in controlling C. elegans life span [23]. A mutation in the ser-1 gene, which encodes a 5-HT2-like receptor [16], dramatically increased life span (by 46%) and significantly enhanced thermotolerance and UV resistance in the worms [13]. These finding may provide an explanation for our previous data that EGb 761 extends life span [24]; an effect that could be partially due to bilobalide modulation of the 5-HT system. Supporting this view, another independent study that screened 88,000 compounds for life span extension in C. elegans found that the most potent life span extending compounds are antidepressant drugs that are antagonists of 5HT2A receptors in humans [25]. Despite unfavorable outcome from clinical studies of EGb 761[26], the unique features of its constituents warrant future investigation [6].

The egg-laying assay in C. elegans has long served as a behavioral marker for serotonergic neurotransmission. In the present study, application of exogenous 5-HT stimulated egg-laying in wild type C. elegans [27], which was significantly inhibited in worms fed BB (Fig 1A). In tph-1 mutants, which are deficient in tryptophan hydroxylase, an enzyme essential for synthesis of 5-HT [20], BB was still able to inhibit 5-HT stimulated egg-laying. The inhibition of egg-laying behavior by BB was blocked in mod-1 and ser-4, two 5-HTR mutants (Fig 1B), suggesting that these receptors are required for BB activity in C. elegans 5-HT-stimulated egg-laying behavior. Another possibility is that BB inadvertently affects 5-HTR by effecting dopamine (DA) function. Extensive research performed in rats, has demonstrated that DA can be enhanced or diminished by compounds that interact with specific 5-HTR subtypes [19]. It has been reported that a mutation in MOD-1, which is a 5-HT-gated ion channel similar to mammalian GABA-Glycine-chloride channels, blocks DA inhibition of egg-laying in C. elegans. Previous studies have demonstrated that BB antagonizes GABA and glycine receptors in embryonic cortical slices [28] and it binds GABAA receptors at therapeutically relevant concentrations [10]. Antagonizing 5-HT receptor SER-4 by BB in C. elegans implicates possible beneficial effects in learning and memory. 5-HT1A receptor in mammals is structurally homologues to the SER-4 receptors in C. elegans. In the mammalian system, activation of 5-HT1A receptors causes defects in learning and memory. On the other hand, activation of the 5-HT2A and 5-HT2C receptors facilitates the formation of memory [2].

Although exogenous 5-HT stimulates egg-laying, it has an inhibitory effect on locomotion [14]. 5-HT reduces locomotion rates by inhibiting the release of ACh at the C. elegans neuromuscular junction [22]. This in turn, leads to resistance to the cholinesterase inhibitor aldicarb, shown as reduced paralysis in the worms exposed to aldicarb. For the first time, we observed that a transgenic C. elegans strain that constitutively expresses human Aβ in the muscle cells (CL2006) was resistant to aldicarb (Fig. 4A). Previous reports demonstrated that worms treated with 5-HT receptor antagonist ketanserin and methiothepin became hypersensitive to aldicarb, whereas DA receptor antagonist had no effect [22]. It should be noted that modulation of 5-HT receptors in mammals is subtype and synaptic localization dependent. Activation of 5-HT1A heteroreceptors resulted in a decrease in ACh release [29] and impairment of cognitive functions [30], whereas, activation 5-HT1A autoreceptors can enhance cognition [31].

The restoration of the basal slowing response by BB in the cat-2 mutants was surprising. Although the cat-2 mutants are deficient in tyrosine hydroxylase, the enzyme needed for DA synthesis, it has been shown that DA synthesis can occur through alternative routes and that these worms still have some functioning DA [32], although significantly less than wild type. These results suggest that BB can modulate the interplay between the serotonergic and dopaminergic systems, which is believed to a basic mechanism for synaptic plasticity in the worms [33]. Antagonist of 5-HTR subtypes appear to enhance activation and signaling of neurotransmitter systems that are known to be involved in cognition [34].

It is important to separate the effects of 5-HT on egg-laying and locomotion [35, 36]. While application of exogenous 5-HT stimulates egg-laying [27] it inhibits locomotion [14]. In C. elegans egg-laying circuitry, there are at least three separate responses to 5-HT [37]. Potential interactions of different receptors subtypes [38] could also account for the effects that are seen with BB. MOD-1 and SER-4 have been shown to provide inhibitory input into the egg-laying process [19, 37] and ser-4; mod-1 double mutants actually lay more eggs than wild type animals in the 5-HT stimulated egg-laying assay [38]. It is also important to note that stimulation of egg-laying by 5-HT occurs via receptors expressed in the muscles and inhibition occurs via receptors located in the neurons [37]. Since many of the mechanisms of BB remain unclear, it is possible that its modulation of these behaviors is location specific. So, inhibition of egg-laying behavior and the potentiation of the locomotory behaviors are not necessarily contradictory.

Several studies have demonstrated that antagonism of 5-HT1A receptors is beneficial in cognitive processes. WAY 100635 and NAD-299 (robalzotan) two selective 5-HT1A receptor antagonist, were able to attenuate the impairments in passive avoidance behavior in rats elicited by scopolamine [34]. Also, a new 5-HT1A receptor antagonist, WAY 101405 was able to reverse cognitive impairments caused by scopolamine, in both the novel object recognition and contextual fear condition paradigms in rats [39]. Lecozotan, a 5-HT1A antagonist that has completed phase I clinical trials, was shown to potentiate the stimulated release of glutamate and acetylcholine in the hippocampus [40]. Although we demonstrated in this study that BB can interact with both serotonergic and dopaminergic signaling in C. elegans, its role may be more important in neuroprotection than disease alleviation since there were no observed effects on Aβ toxicity.

In conclusion, bilobalide modulates interplay of 5-HT and dopamine neurotransmission systems. Additional studies for the function of bilobalide in neurotransmitter systems would further our understanding of its neuroprotective properties.

Methods

Materials

Bilobalide (BB), serotonin creatinine sulfate complex (5-HT), dopamine hydrochloride (DA) and aldicarb were all purchased from Sigma (St. Louis, MO). Stock solutions of all chemicals were made either with 95% ethanol, M9 Buffer or distilled water. The final concentration of ethanol, when dissolved in the food (Escherichia coli strain OP50) did not exceed 0.01%. All chemicals/drugs for treatment of experimental animals were added directly to the OP50 food source.

C. elegans strains

mod-1 (ok103), ser-4(C. elegans Gene Knockout Consortium), tph-1 (mg280), mod-5(n3314), cat-2(e1112) and N2 (Bristol) were all obtained from the Caenorhabditis Genetics Center, University of Minnesota. The transgenic strain CL2006 has the unc-54/Aβ1–42 and rol-6 (su1066) transgenes integrated into the worm's chromosome and it constituently expresses Aβ1–42 in the muscle cells [41]. CL2006 was a gift from Dr. CD Link from the University of Colorado-Boulder. All animals were grown on solid nematode growth media (NGM), with 100 μl OP50 containing either vehicles or chemicals, at 20°C from egg or L1 (day 1 young larvae) until assayed, unless stated otherwise.

C. elegans maintenance and treatment

All animals were cultured at 20°C under standard laboratory conditions. To age synchronize animals, adult nematodes were transferred to fresh NGM plates and allowed to lay eggs for 2–4 h. Isolated hatchlings from the synchronized day 1 young larvae (L1), were cultured on fresh NGM plates in a 20°C temperature-controlled incubator (model 2005; Sheldon Manufacturing, Cornelius, OR). The worms were fed the drugs either from stage L1 (1 d of age) or starting from the egg.

Behavioral Studies

Egg-laying Assay

The average number of eggs released per hour was quantified according to a well established assay [18, 19, 27], except animals were assayed ~40 ± 2 h after the L4 young larvae stage, so that animals could be fed the drugs for a full three days. Age-synchronized well-fed L4 young larvae were transferred to fresh plates seeded with OP50 containing either vehicle or Bilobalide and allowed to develop for ~20 ± 2 h at 20°C. After another 20 h, the resultant young adults were assayed for their response to the drugs. Individual young adults were transferred to a 96-well plate containing 100 μl of a 5 mg/ml solution of serotonin creatinine sulfate complex dissolved in M9. The number of eggs released at room temperature was scored after 60 min.

Life span Assay

The life span assay was performed as described previously [42]. Age synchronized animals were fed with 0.3 μM of Bilobalide from L4 and maintained at 20°C. Animals were transferred daily for 4 consecutive days until they ceased to lay eggs to avoid overlapping generations. Worms were scored as dead if they did not respond to a touch stimulus by a platinum loop.

Aldicarb Sensitivity Assay

The acetylcholinesterase inhibitor aldicarb, results in a toxic accumulation of acetylcholine (ACh) in the neuromuscular junction. Aldicarb sensitivity was assayed in adult day 1 animals by analyzing the onset of paralysis following treatment with 1 mM aldicarb. Animals were prodded every 20 min with a platinum wire loop following exposure to drug. As indicated, some worms were pre-incubated with 5-HT for 2 h prior to the assay. Worms were non-treated or fed with BB (0.3 μM), starting from the egg.

Locomotory Rate Assays

Assays were performed according to Sawin et al (Sawin, 2000) with slight modifications. A ring of E. coli strain OP50 was placed on a 5 cm Petri plate containing NGM. Assay plates were freshly spread with bacteria and allowed to incubate at room temperature overnight. Age synchronized young adult hermaphrodites (~20 ± 2 hrs after L4 larval stage) were tested. For the well-fed animals, we measured the locomotory rate by removing 5 animals from bacteria-containing plates and washing the animals three times in S basal buffer, and then quickly transferring them to an assay plate. Any buffer that remained on the plates was absorbed with a Kimwipe. Five minutes after the worms were transferred; we measured the number of body bends in 30 second intervals for each of the 5 animals that were on the assay plate. The angle of a body bend is typically more than 90°.

For the starved animals, 5–10 animals were washed free of bacteria in S basal buffer (3X's) and then transferred to a 5 cm NGM agar plate that was free of bacteria. Excess buffer was removed with a Kimwipe. The animals were incubated on these plates for 30 minutes at room temperature. After 30 minutes of starvation, five worms were transferred to assay plates and the locomotory rate was measured as described above.

Neurotransmitter Pre-treatment

Solutions of dopamine hydrochloride (50 mM) were prepared in M9 buffer and 400 μl of the solution or M9 was added to each 5 cm plate containing ~10 ml of agar and a bacterial lawn so that the final concentration of DA solution would be ~2 mM. The plates were allowed to dry at 1 hr at room temperature and then 40–50 worms (treated and untreated were transferred to each plate. Animals were incubated for 2 hrs at 20°C and then assayed according to the locomotory assay mentioned above [12].

Data Analysis

Data are analyzed for statistical significance by independent Student's t test of untreated and drug-treated animal groups using Origin 6.0 software (Microcal Software, Northampton, MA). In all cases a value of p < 0.05 indicates a significant difference.

Abbreviations

AD:

Alzheimer's disease

BB:

bilobalide

5-HT:

serotonin

DA:

dopamine

5-HTR:

serotonin receptors

Aβ:

amyloid beta peptide

BSR:

basal slowing response

ESR:

enhanced slowing response.

References

  1. 1.

    Mattson MP, Maudsley S, Martin B: BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004, 27: 589-94. 10.1016/j.tins.2004.08.001.

  2. 2.

    Buhot MC, Martin S, Segu L: Role of serotonin in memory impairment. Ann Med. 2000, 32: 210-21. 10.3109/07853890008998828.

  3. 3.

    Francis PT, Pangalos MN, Bowen DM: Animal and drug modelling for Alzheimer synaptic pathology. Prog Neurobiol. 1992, 39: 517-45. 10.1016/0301-0082(92)90005-Y.

  4. 4.

    Harder JA, Ridley RM: The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology. 2000, 39: 547-52. 10.1016/S0028-3908(99)00179-3.

  5. 5.

    Banasr M, Hery M, Printemps R, Daszuta A: Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004, 29: 450-60. 10.1038/sj.npp.1300320.

  6. 6.

    Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y: Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci. 2006, 26: 13102-13. 10.1523/JNEUROSCI.3448-06.2006.

  7. 7.

    Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J: Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 1999, 360: 609-15. 10.1007/s002109900131.

  8. 8.

    Chandrasekaran K, Mehrabian Z, Spinnewyn B, Drieu K, Fiskum G: Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res. 2001, 922: 282-92. 10.1016/S0006-8993(01)03188-2.

  9. 9.

    Klein J, Chatterjee SS, Loffelholz K: Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res. 1997, 755: 347-50. 10.1016/S0006-8993(97)00239-4.

  10. 10.

    Kiewert C, Kumar V, Hildmann O, Rueda M, Hartmann J, Naik RS, Klein J: Role of GABAergic antagonism in the neuroprotective effects of bilobalide. Brain Res. 2007, 1128: 70-8. 10.1016/j.brainres.2006.10.042.

  11. 11.

    Jones FA, Chatterjee SS, Davies JA: Effects of bilobalide on amino acid release and electrophysiology of cortical slices. Amino Acids. 2002, 22: 369-79. 10.1007/s007260200021.

  12. 12.

    Sawin ER, Ranganathan R, Horvitz HR: C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron. 2000, 26: 619-31. 10.1016/S0896-6273(00)81199-X.

  13. 13.

    Murakami H, Bessinger K, Hellmann J, Murakami S: Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans. Neurobiol Aging. 2007, 29 (7): 1093-100. 10.1016/j.neurobiolaging.2007.01.013.

  14. 14.

    Ranganathan R, Cannon SC, Horvitz HR: MOD-1 is a serotonin-gated chloride channel that modulates locomotory behaviour in C. elegans. Nature. 2000, 408: 470-5. 10.1038/35044083.

  15. 15.

    Olde B, McCombie WR: Molecular cloning and functional expression of a serotonin receptor from Caenorhabditis elegans. J Mol Neurosci. 1997, 8: 53-62. 10.1007/BF02736863.

  16. 16.

    Hamdan FF, Ungrin MD, Abramovitz M, Ribeiro P: Characterization of a novel serotonin receptor from Caenorhabditis elegans: cloning and expression of two splice variants. J Neurochem. 1999, 72: 1372-83. 10.1046/j.1471-4159.1999.721372.x.

  17. 17.

    Hobson RJ, Geng J, Gray AD, Komuniecki RW: SER-7b, a constitutively active Galphas coupled 5-HT7-like receptor expressed in the Caenorhabditis elegans M4 pharyngeal motorneuron. J Neurochem. 2003, 87: 22-9. 10.1046/j.1471-4159.2003.01967.x.

  18. 18.

    Weinshenker D, Garriga G, Thomas JH: Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. J Neurosci. 1995, 15: 6975-85.

  19. 19.

    Dempsey CM, Mackenzie SM, Gargus A, Blanco G, Sze JY: Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics. 2005, 169: 1425-36. 10.1534/genetics.104.032540.

  20. 20.

    Sze JY, Victor M, Loer C, Shi Y, Ruvkun G: Food and metabolic signalling defects in a Caenorhabditis elegans serotonin-synthesis mutant. Nature. 2000, 403: 560-4. 10.1038/35000609.

  21. 21.

    Ranganathan R, Sawin ER, Trent C, Horvitz HR: Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine. J Neurosci. 2001, 21: 5871-84.

  22. 22.

    Nurrish S, Segalat L, Kaplan JM: Serotonin inhibition of synaptic transmission: Galpha(0) decreases the abundance of UNC-13 at release sites. Neuron. 1999, 24: 231-42. 10.1016/S0896-6273(00)80835-1.

  23. 23.

    Murakami H, Murakami S: Serotonin receptors antagonistically modulate Caenorhabditis elegans longevity. Aging Cell. 2007, 6: 483-8. 10.1111/j.1474-9726.2007.00303.x.

  24. 24.

    Wu Z, Smith JV, Paramasivam V, Butko P, Khan I, Cypser JR, Luo Y: Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol (Noisy-le-grand). 2002, 48: 725-31.

  25. 25.

    Petrascheck M, Ye X, Buck LB: An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature. 2007, 450: 553-6. 10.1038/nature05991.

  26. 26.

    DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD: Ginkgo biloba for prevention of dementia: a randomized controlled trial. Jama. 2008, 300: 2253-62. 10.1001/jama.2008.683.

  27. 27.

    Trent C, Tsuing N, Horvitz HR: Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics. 1983, 104: 619-47.

  28. 28.

    Ivic L, Sands TT, Fishkin N, Nakanishi K, Kriegstein AR, Stromgaard K: Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA(A) receptors. J Biol Chem. 2003, 278: 49279-85. 10.1074/jbc.M304034200.

  29. 29.

    Consolo S, Ramponi S, Ladinsky H, Baldi G: A critical role for D1 receptors in the 5-HT1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex. Brain Res. 1996, 707: 320-3. 10.1016/0006-8993(95)01369-5.

  30. 30.

    Wolff M, Costet P, Gross C, Hen R, Segu L, Buhot MC: Age-dependent effects of serotonin-1A receptor gene deletion in spatial learning abilities in mice. Brain Res Mol Brain Res. 2004, 130: 39-48. 10.1016/j.molbrainres.2004.07.012.

  31. 31.

    Carli M, Balducci C, Millan MJ, Bonalumi P, Samanin R: S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999, 128: 1207-14. 10.1038/sj.bjp.0702915.

  32. 32.

    Sanyal S, Wintle RF, Kindt KS, Nuttley WM, Arvan R, Fitzmaurice P, Bigras E, Merz DC, Hebert TE, Kooy van der D, Schafer WR, Culotti JG, Van Tol HH: Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. Embo J. 2004, 23: 473-82. 10.1038/sj.emboj.7600057.

  33. 33.

    Murakami H, Bessinger K, Hellmann J, Murakami S: Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans. Neurobiol Aging. 2008, 29: 1093-100. 10.1016/j.neurobiolaging.2007.01.013.

  34. 34.

    Misane I, Ogren SO: Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology. 2003, 28: 253-64. 10.1038/sj.npp.1300024.

  35. 35.

    Horvitz HR, Chalfie M, Trent C, Sulston JE, Evans PD: Serotonin and octopamine in the nematode Caenorhabditis elegans. Science. 1982, 216: 1012-4. 10.1126/science.6805073.

  36. 36.

    Waggoner LE, Zhou GT, Schafer RW, Schafer WR: Control of alternative behavioral states by serotonin in Caenorhabditis elegans. Neuron. 1998, 21: 203-14. 10.1016/S0896-6273(00)80527-9.

  37. 37.

    Carnell L, Illi J, Hong SW, McIntire SL: The G-protein-coupled serotonin receptor SER-1 regulates egg laying and male mating behaviors in Caenorhabditis elegans. J Neurosci. 2005, 25: 10671-81. 10.1523/JNEUROSCI.3399-05.2005.

  38. 38.

    Hapiak VM, Hobson RJ, Hughes L, Smith K, Harris G, Condon C, Komuniecki P, Komuniecki RW: Dual excitatory and inhibitory serotonergic inputs modulate egg laying in Caenorhabditis elegans. Genetics. 2009, 181: 153-63. 10.1534/genetics.108.096891.

  39. 39.

    Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, Lee van der H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE: Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexan e carboxamide (WAY-101405). J Pharmacol Exp Ther. 2008, 325: 134-45. 10.1124/jpet.107.133082.

  40. 40.

    Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W: Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther. 2005, 314: 1274-89. 10.1124/jpet.105.086363.

  41. 41.

    Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA. 1995, 92: 9368-72. 10.1073/pnas.92.20.9368.

  42. 42.

    Brown MK, Evans JL, Luo Y: Beneficial effects of natural antioxidants EGCG and alpha-lipoic acid on life span and age-dependent behavioral declines in Caenorhabditis elegans. Pharmacol Biochem Behav. 2006, 85: 620-8. 10.1016/j.pbb.2006.10.017.

Download references

Acknowledgements

We would like to thank the C. elegans Gene Knockout Consortium for strains and the National Center for Complementary and Alternative Medicine, grant R01AT001928-03A1 (YL) for financial support.

Author information

Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, USA

    • Marishka K Brown
    •  & Yuan Luo

  2. Center for integrative Medicine, School of Medicine, University of Maryland, Baltimore, USA

    • Yuan Luo

Authors

  1. Search for Marishka K Brown in:

  2. Search for Yuan Luo in:

Corresponding author

Correspondence to Yuan Luo.

Additional information

Authors' contributions

MKB carried out all behavioral assays, statistical analysis and drafted the manuscript. YL participated in general design of the experiments and edited the final version of the manuscript. All authors have read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Authors’ original file for figure 4

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Aldicarb
  • Ginkgo Biloba Extract
  • Nematode Growth Medium
  • Wild Type Worm
  • Body Bend

BMC Neuroscience

ISSN: 1471-2202

Contact us